Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this first in human study is to evaluate the safety of treatment with
autologous T cells genetically modified to express a CER (chimeric endocrine receptor)
targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without
conditioning chemotherapy, in participants with recurrent or persistent ovarian, fallopian
tube, or primary peritoneal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute